Previous studies have shown that the glutaminolysis pathway plays an important protective role in experimental colitis models and that targeting Gls1 (the first enzyme in the glutaminolysis pathway) is an effective therapy for autoimmune diseases.16, 20, 22, 23, 33 In this study, Gls1 was highly expressed in the intestines of CD patients and IL‐10−/− mice. This evidence concerns the gene GLS and colitis.